Literature DB >> 9466660

Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection.

S Faisst1, D Guittard, A Benner, J Y Cesbron, J R Schlehofer, J Rommelaere, T Dupressoir.   

Abstract

Parvoviruses of rodents are endowed with oncosuppressive properties. In particular, parvoviral infections protect host animals from spontaneous and chemical- or virus-induced tumour initiation in laboratory animals. The present study was undertaken to substantiate the capacity of parvovirus H-1 to inhibit therapeutically the growth of established tumours originating from human carcinoma cells implanted in recipient mice. To this end, quickly growing s.c. carcinomas were established by injection of human cervical carcinoma cells (HeLa) into immunodeficient (SCID) mice. Tumour-bearing mice subsequently were inoculated with H-1 at various multiplicities of infection. H-1 virus infection led to regression of tumours, the onset and efficiency of which were dose-dependent.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466660     DOI: 10.1002/(sici)1097-0215(19980209)75:4<584::aid-ijc15>3.0.co;2-9

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Exploring the contribution of distal P4 promoter elements to the oncoselectivity of Minute Virus of Mice.

Authors:  Justin Paglino; Erik Burnett; Peter Tattersall
Journal:  Virology       Date:  2006-12-18       Impact factor: 3.616

2.  The parvoviral capsid controls an intracellular phase of infection essential for efficient killing of stepwise-transformed human fibroblasts.

Authors:  Justin Paglino; Peter Tattersall
Journal:  Virology       Date:  2011-05-20       Impact factor: 3.616

3.  Structural characterization of H-1 parvovirus: comparison of infectious virions to empty capsids.

Authors:  Sujata Halder; Hyun-Joo Nam; Lakshmanan Govindasamy; Michèle Vogel; Christiane Dinsart; Nathalie Salomé; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

4.  Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species.

Authors:  Georgi Hristov; Melanie Krämer; Junwei Li; Nazim El-Andaloussi; Rodrigo Mora; Laurent Daeffler; Hanswalter Zentgraf; Jean Rommelaere; Antonio Marchini
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

5.  B1 lymphocytes and myeloid dendritic cells in lymphoid organs are preferential extratumoral sites of parvovirus minute virus of mice prototype strain expression.

Authors:  Zahari Raykov; Larissa Savelyeva; Ginette Balboni; Thomas Giese; Jean Rommelaere; Nathalia A Giese
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Induction of an embryonic mouse innate immune response following inoculation in utero with minute virus of mice.

Authors:  Irina Rostovsky; Claytus Davis
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

7.  Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.

Authors:  Xavier Allaume; Nazim El-Andaloussi; Barbara Leuchs; Serena Bonifati; Amit Kulkarni; Tiina Marttila; Johanna K Kaufmann; Dirk M Nettelbeck; Jürgen Kleinschmidt; Jean Rommelaere; Antonio Marchini
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

8.  Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells.

Authors:  Claudia Wrzesinski; Lia Tesfay; Nathalie Salomé; Jean-Claude Jauniaux; Jean Rommelaere; Jan Cornelis; Christiane Dinsart
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

9.  Replicating parvoviruses that target colon cancer cells.

Authors:  M Malerba; L Daeffler; J Rommelaere; R D Iggo
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.

Authors:  Assia L Angelova; Marc Aprahamian; Ginette Balboni; Henri-Jacques Delecluse; Regina Feederle; Irina Kiprianova; Svitlana P Grekova; Angel S Galabov; Mathias Witzens-Harig; Anthony D Ho; Jean Rommelaere; Zahari Raykov
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.